$558.5 M

CCXI Mkt cap, 13-Feb-2019
ChemoCentryx Net income (Q3, 2018)-10.9 M
ChemoCentryx EBIT (Q3, 2018)-11.5 M
ChemoCentryx Cash, 30-Sep-201824.1 M
ChemoCentryx EV549.1 M

ChemoCentryx Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

11.9m82.5m

R&D expense

33.5m33.2m37.9m49.5m

General and administrative expense

11.6m14.5m14.7m16.5m

Operating expense total

45.2m47.7m52.7m66.0m

EBIT

(39.1m)(47.7m)(40.7m)16.5m

EBIT margin, %

(341%)20%

Interest expense

59.0k4.0k

Interest income

501.0k384.0k757.0k1.4m

Net Income

(38.7m)(47.3m)(40.0m)17.9m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.8m4.3m8.2m8.9m9.0m9.5m

R&D expense

8.2m8.1m9.0m7.5m8.4m8.6m7.9m11.2m9.1m8.4m10.0m14.3m12.3m14.7m17.8m15.1m

General and administrative expense

2.9m3.5m3.4m3.5m3.7m3.6m3.8m4.1m3.9m3.2m4.6m4.2m3.6m4.7m4.7m5.4m

Operating expense total

11.1m11.7m12.4m11.1m12.1m12.2m11.7m15.3m12.9m11.6m14.5m18.5m15.9m19.4m22.5m20.5m

EBIT

(9.6m)(11.7m)(12.4m)(11.1m)(12.1m)(12.2m)(11.7m)(15.3m)(10.1m)(7.3m)(6.3m)(9.6m)(6.9m)(9.9m)(7.5m)(11.5m)

EBIT margin, %

(363%)(172%)(77%)(107%)(77%)(103%)

Interest expense

14.0k11.0k6.0k4.0k11.0k4.0k174.0k181.0k423.0k

Interest income

134.0k146.0k129.0k116.0k103.0k100.0k95.0k86.0k161.0k259.0k317.0k336.0k350.0k613.0k792.0k1.1m

Net Income

(9.4m)(11.5m)(12.3m)(10.9m)(12.0m)(12.1m)(11.6m)(15.2m)(10.0m)(7.1m)(6.0m)(9.2m)(6.6m)(9.4m)(6.9m)(10.9m)

ChemoCentryx Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.3m16.1m12.8m12.0m40.0m

Accounts Receivable

30.2m51.1m

Inventories

596.0k972.0k757.0k722.0k

Current Assets

134.3m74.3m72.0m148.7m179.8m

PP&E

1.4m1.2m949.0k905.0k1.2m

Total Assets

152.4m117.0m78.2m155.9m189.3m

Accounts Payable

909.0k748.0k675.0k671.0k1.4m

Short-term debt

Current Liabilities

6.9m8.2m5.5m38.3m32.9m

Long-term debt

4.7m

Total Debt

4.7m

Total Liabilities

7.1m5.6m106.0m110.1m

Additional Paid-in Capital

318.1m328.4m339.6m357.0m368.6m

Retained Earnings

(172.9m)(219.8m)(267.1m)(307.1m)(289.2m)

Total Equity

145.3m108.6m72.5m49.9m79.3m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0 x

Financial Leverage

1 x1.1 x1.1 x3.1 x2.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

22.3m11.6m13.1m20.9m25.4m11.6m14.6m13.4m21.9m13.9m19.0m21.5m18.0m30.6m68.8m24.1m

Accounts Receivable

175.0k120.0k30.2m218.0k530.0k1.7m164.0k336.0k

Inventories

1.3m

Current Assets

125.6m133.7m100.8m86.1m76.1m71.4m74.2m65.2m127.0m122.7m119.9m124.2m122.4m149.8m184.9m176.1m

PP&E

1.4m1.3m1.2m1.2m1.2m1.1m1.0m925.0k858.0k778.0k984.0k1.0m970.0k1.1m1.6m1.6m

Total Assets

160.0m144.5m135.5m126.8m107.3m96.3m87.2m67.4m142.3m133.7m152.4m140.5m127.9m181.8m206.6m190.8m

Accounts Payable

692.0k710.0k690.0k1.0m809.0k1.0m615.0k1.3m513.0k840.0k819.0k1.4m1.4m449.0k1.0m576.0k

Current Liabilities

6.5m7.1m7.9m8.1m7.7m5.2m5.5m7.4m23.0m26.2m42.5m44.7m44.4m76.6m68.7m61.3m

Long-term debt

4.7m14.7m14.7m

Total Debt

4.7m14.7m14.7m

Total Liabilities

6.8m7.3m8.3m5.4m7.5m82.7m79.4m99.6m90.7m156.2m177.7m169.3m

Additional Paid-in Capital

316.5m321.5m324.0m326.1m331.2m334.7m336.9m342.1m351.7m353.7m359.4m363.3m366.2m371.7m381.9m385.3m

Retained Earnings

(163.3m)(184.4m)(196.7m)(207.6m)(231.8m)(243.9m)(255.5m)(282.3m)(292.3m)(299.4m)(313.1m)(322.3m)(328.9m)(345.9m)(352.8m)(363.7m)

Total Equity

153.2m137.2m127.4m118.5m99.4m90.9m81.5m59.8m59.5m54.4m46.3m40.9m37.3m25.5m28.9m21.5m

Debt to Equity Ratio

0.2 x0.5 x0.7 x

Debt to Assets Ratio

0 x0.1 x0.1 x

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x2.4 x2.5 x3.3 x3.4 x3.4 x7.1 x7.1 x8.9 x

ChemoCentryx Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.7m)(46.9m)(47.3m)(40.0m)17.9m

Depreciation and Amortization

576.0k543.0k477.0k348.0k418.0k

Accounts Receivable

(30.2m)(20.9m)

Inventories

Accounts Payable

159.0k(161.0k)(73.0k)(4.0k)729.0k

Cash From Operating Activities

(33.3m)(34.3m)(39.3m)39.1m4.9m

Purchases of PP&E

(554.0k)(218.0k)(304.0k)(723.0k)

Cash From Investing Activities

(31.7m)38.3m33.9m(48.8m)15.6m

Cash From Financing Activities

66.8m1.8m2.2m8.8m7.5m

Interest Paid

26.0k137.0k137.0k137.0k

Quarterly

ChemoCentryx Ratios

USDY, 2018

EV/EBIT

-47.6 x

EV/CFO

17.3 x

Debt/Equity

0.7 x

Debt/Assets

0.1 x

Financial Leverage

8.9 x
Report incorrect company information

ChemoCentryx Employee Rating

2.39 votes
Culture & Values
2.4
Work/Life Balance
2.0
Senior Management
2.1
Salary & Benefits
2.4
Career Opportunities
2.3
Source